79 results on '"Verburg, Frederik A"'
Search Results
2. Replacing Lu-177 with Tb-161 in DOTA-TATE and PSMA-617 therapy: potential dosimetric implications for activity selection
3. The EANM guideline on radioiodine therapy of benign thyroid disease
4. Normal organ dosimetry for thyroid cancer patients treated with radioiodine as part of the multi-centre multi-national Horizon 2020 MEDIRAD project
5. Results from an EANM survey on time estimates and personnel responsible for main tasks in molecular radiotherapy dosimetry
6. The EANM practice guidelines for parathyroid imaging
7. Current research topics in FAPI theranostics: a bibliometric analysis
8. Ruolo dell’imaging medico nucleare nell’iperparatiroidismo
9. To give or not to give? A critical appraisal of a clinical trial on radioiodine treatment
10. Asinus in Tegulis—basing stark warning messages on insufficient methodology
11. EANM dosimetry committee recommendations for dosimetry of 177Lu-labelled somatostatin-receptor- and PSMA-targeting ligands
12. The limits of the “holy gray” in radioembolization and beyond
13. A dedicated paediatric [18F]FDG PET/CT dosage regimen
14. Positive [18F]fluoroethyltyrosine PET/MRI in suspected recurrence of growth hormone–producing pituitary adenoma in a paediatric patient
15. Setting up a quantitative SPECT imaging network for a European multi-centre dosimetry study of radioiodine treatment for thyroid cancer as part of the MEDIRAD project
16. To go where no one has gone before: the necessity of radiobiology studies for exploration beyond the limits of the “Holy Gray” in radionuclide therapy
17. Intracranial hemangiopericytoma showing excellent uptake on arterial injection of [68Ga]DOTATATE
18. 177Lu-PSMA for advanced prostate cancer: are we ready to play big?
19. Perioperative diagnostics of patients referred for radioiodine therapy of differentiated thyroid carcinoma: referral center experience in an iodine-insufficient country
20. EANM position paper on article 56 of the Council Directive 2013/59/Euratom (basic safety standards) for nuclear medicine therapy
21. Correction to: Higher thyroid hormone levels and cancer
22. Higher thyroid hormone levels and cancer
23. No time like the present: time to re-think our habits in science and continuous medical education?
24. New! F-18-based PET/CT for sodium-iodine-symporter-targeted imaging!
25. Brief progress report from the intersocietal working group on differentiated thyroid cancer
26. “Quid autem vides festucam in oculo fratris tui et trabem in oculo tuo non vide” on the hyperthyroidism-induced mortality and antithyroid drug-induced side effects in the era of radioiodine fake news
27. Prostate specific membrane antigen (PSMA) in urothelial cell carcinoma (UCC) is associated with tumor grading and staging
28. Errare humanum est, sed in errare perseverare diabolicum: methodological errors in the assessment of the relationship between I-131 therapy and possible increases in the incidence of malignancies
29. Differentiated thyroid cancer patients potentially benefitting from postoperative I-131 therapy: a review of the literature of the past decade
30. EANM practice guideline for PET/CT imaging in medullary thyroid carcinoma
31. Use of anti-thyroid drugs in patients with hyperthyroidism: a case for shared decision-making
32. Sonographic diagnosis of thyroid cancer with support of AI
33. Correction to: Evaluation of 167 Gene Expression Classifier (GEC) and ThyroSeq v2 Diagnostic Accuracy in the Preoperative Assessment of Indeterminate Thyroid Nodules: Bivariate/HROC Meta-analysis
34. Evaluation of 167 Gene Expression Classifier (GEC) and ThyroSeq v2 Diagnostic Accuracy in the Preoperative Assessment of Indeterminate Thyroid Nodules: Bivariate/HROC Meta-analysis
35. I-131 as adjuvant treatment for differentiated thyroid carcinoma may cause an increase in the incidence of secondary haematological malignancies: an “inconvenient” truth?
36. Postoperative serum thyroglobulin and neck ultrasound to drive decisions about iodine-131 therapy in patients with differentiated thyroid carcinoma: an evidence-based strategy?
37. Balancing benefit and risk in TSH management of DTC
38. A new perspective for nuclear medicine: expanding the indications for PSMA targeted imaging and therapy
39. Radioiodine treatment after surgery for differentiated thyroid cancer: a reasonable option
40. One-stop-shop radioiodine dosimetry in patients with Graves’ disease
41. Evaluation of 131I scintigraphy and stimulated thyroglobulin levels in the follow up of patients with DTC: a retrospective analysis of 1420 patients
42. The reconstruction algorithm used for [68Ga]PSMA-HBED-CC PET/CT reconstruction significantly influences the number of detected lymph node metastases and coeliac ganglia
43. Adjuvant post-operative I-131 therapy in differentiated thyroid carcinoma: are the 2015 ATA guidelines an exact science or a dark art?
44. Searching for the most effective thyrotropin (TSH) threshold to rule-out autonomously functioning thyroid nodules in iodine deficient regions
45. PSMA PET–CT in initial prostate cancer staging
46. Molecular imaging using PSMA PET/CT versus multiparametric MRI for initial staging of prostate cancer: comparing apples with oranges?
47. Detection of recurrent prostate cancer lesions before salvage lymphadenectomy is more accurate with 68Ga-PSMA-HBED-CC than with 18F-Fluoroethylcholine PET/CT
48. Extent of disease in recurrent prostate cancer determined by [68Ga]PSMA-HBED-CC PET/CT in relation to PSA levels, PSA doubling time and Gleason score
49. Endogenous TSH levels at the time of 131I ablation do not influence ablation success, recurrence-free survival or differentiated thyroid cancer-related mortality
50. 68Ga-PSMA-HBED-CC PET/CT: where molecular imaging has an edge over morphological imaging
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.